CRVS - Corvus Pharmaceuticals, Inc.

15.54
-1.200   -7.722%

Share volume: 1,241,690
Last Updated: 04-20-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$16.74
-1.20
-0.07%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
21%
Profitability 25%
Dept financing 4%
Liquidity 48%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.32%
1 Month
13.02%
3 Months
-29.84%
6 Months
115.83%
1 Year
382.61%
2 Year
979.17%
Key data
Stock price
$15.54
P/E Ratio 
N/A
DAY RANGE
$15.52 - $16.90
EPS 
-$0.19
52 WEEK RANGE
$3.16 - $26.95
52 WEEK CHANGE
$366.67
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
83.992 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-05-2025
BETA 
1.73
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,188,421
AVERAGE 30 VOLUME 
$1,035,214
Company detail
CEO: Richard A. Miller
Region: US
Website: corvuspharma.com
Employees: 30
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Corvus Pharmaceuticals, Inc. focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company was incorporated in 2014 and is based in Burlingame, California.

Recent news